BMYCelgeneFinished
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Hematologic Neoplasm · Neoplasms · Hematologic Malignancies
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 5 (final count)
- Started
- Oct 22, 2015
- Main results expected
- Apr 14, 2025
- Fully finished
- Apr 14, 2025
- Results posted
- Apr 2, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Treatment Emergent Adverse Events
Measured over: From informed consent signed (Day 1) and until 28 days after the last dose of CC-486, or until the treatment discontinuation visit, whichever was later (up to approximately 90 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02494258 · record last updated 2026-04-02 · checked 2026-11-09 15:42 UTC